Bruce A. Feinberg, DO: Would you still want to be doing pharmacovigilance postmarket release for the Mylan product if, and when, it comes to market?
Hope S. Rugo, MD: There’s no question that pharmacovigilance is incredibly important for all agents. I always tell people, “This is a biosimilar, so it’s very different from using another drug.” But, when you think about it, when any drug goes on the market, pharmacovigilance is incredibly important. In something as simple as a nonsteroidal, we saw a drug go off the market, Vioxx, because of postmarketing vigilance. So, I think that this is very important for all agents, when you have a new product going on the market. And a biosimilar is a new product, so pharmacovigilance is going to be critical. That is part of the regulatory direction for these agents, so pharmacovigilance will be part of this.
In terms of whether the Mylan product will go on the market or not, I think the study met all of the criteria set forth by the regulatory agents. So, it’s more of an issue of production and how production will happen in terms of approval or not. I don’t think there’s any question that these drugs will move forward. And, in the Oncology Drugs Advisory Committee meeting, recently, which was the first to evaluate oncology therapeutics, for both oncology therapeutics that were reviewed— bevacizumab in the morning and our trastuzumab product in the afternoon—there was a 100% vote of “Yes.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.